JHL Biotech to Develop and Manufacture GMP-grade Antigen for Taiwan’s Leading Covid-19 Vaccine Produced by AdimmunePosted by On

Cannabis in growing house

JHL to manufacture antigen for Adimmune Covid-19 vaccine

JHL to manufacture antigen for Adimmune Covid-19 vaccine

JHL Biotech

JHL Biotech

JHL is pleased to announce a collaboration with Adimmune, a Taiwanese vaccine company, to manufacture and supply the antigen for their leading Covid-19 vaccine.

HSINCHU, TAIWAN, September 15, 2020 /EINPresswire.com/ — JHL Biotech, Inc. is extremely honored and proud to announce a signing of a Master Service Agreement (“MSA”) with Adimmune Corporation, a Taiwanese vaccine company, to manufacture and supply the Antigen for their leading Covid-19 vaccine candidate. In full support of the Taiwan Government’s diligence and awareness for Covid-19 prevention, as well as to ensure abundant vaccine doses for the Taiwanese population, Adimmune has been continually searching for qualified partners for commercial production of antigens, which led to a collaboration with JHL. Furthermore, since this pandemic is directly related to public health…

Original Author Link click here to read complete story..

News

AdimmuneAntigenBiotechCOVID19developGMPgradeJHLleadingmanufactureProducedTaiwansvaccine

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.